Advertisement

Lipids

, Volume 51, Issue 1, pp 75–83 | Cite as

Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels

  • Celia Rodríguez-Pérez
  • Vanu Ramkumar Ramprasath
  • Shuaihua Pu
  • Ali Sabra
  • Rosa Quirantes-Piné
  • Antonio Segura-Carretero
  • Peter JH Jones
Original Article

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that regulates cholesterol metabolism by promoting LDL receptor degradation in the liver and has recently been proposed as a therapeutic target in the management of hyperlipidaemia. We investigated the impact of dietary fat on the metabolism of sterols and on plasma PCSK9 concentrations to explore likely clinical usefulness. In a post hoc analysis of a double-blind randomised crossover controlled feeding trial, the Canola Oil Multicenter Intervention Trial (COMIT), volunteers (n = 54) with at least one condition related to metabolic syndrome consumed diets with one of the following treatment oils in beverages: (1) conventional canola oil (Canola); (2) canola oil rich in docosahexanoic acid (DHA) (CanolaDHA); and (3) high-oleic acid canola oil (CanolaOleic). The enrichment in oleic acid resulted in lower plasma cholesterol concentration compared with diets enriched in DHA. Contrarily, DHA-enriched oil significantly decreased plasma PCSK9 and triacylglycerols levels, but increased circulating levels of sterols. The variations in lathosterol, sitosterol, and campesterol indicate that plasma PCSK9 levels are sensitive to changes in cholesterol synthesis and/or absorption. There was a significant correlation between plasma PCSK9 levels and plasma triacylglicerol and apolipoprotein B levels, which was not affected by dietary fat. Therefore, our results suggest that the impact of dietary fats should not be discarded as complementary treatment in the management of patients with hyperlipidaemia. These findings should be considered in the analysis of ongoing studies and may represent a cautionary note in the treatment of patients with cardiovascular risk.

Keywords

PCSK9 Fatty acids Docosahexaenoic acid Sterols Hyperlipidaemia 

Abbreviations

ADH

Autosomal dominant hypercholesterolaemia

Apo

Apoprotein

Canola

Conventional canola oil

CanolaDHA

Canola oil rich in DHA

CanolaOleic

High-oleic acid canola oil

CVD

Cardiovascular disease

DHA

Docosahexanoic acid

FID

Flame ionization detector

HMG-CoA

3-hydroxy-3-methylglutaryl coenzyme A

LDL

Low-density lipoprotein

LDLR

LDL receptor

MUFA

Monounsaturated fatty acids

PCSK9

Proprotein convertase subtilisin/kexin type 9

PPARγ

Peroxisome proliferator-activated receptor γ

PUFA

Polyunsaturated fatty acids

SREBP

Sterol response element-binding proteins

TAG

Triacylglycerols

Notes

Acknowledgments

We gratefully acknowledge Khatima Khalloufi and Mohammad Abdullah from the Richardson Centre for Functional Foods and Nutraceuticals for her technical laboratory support and his help with the ELISA tests, respectively. We would like to express our gratitude to Jorge Joven, Director of Laboratoris Clínics i de la Unitat de Recerca Biomèdica (URB-CRB), for his kind advice and suggestions regarding the manuscript organisation. The authors are also grateful to the Spanish Ministry of Economy and Competitiveness (MINECO) for a FPU fellowship AP2010-1551 (C. Rodríguez-Pérez), a “Personal técnico de apoyo” Grant PTA2012-6956-E (R. Quirantes-Piné) and to CEIBiotic’s predoctoral mobility Grant (C. Rodríguez-Pérez).

Compliance with ethical standards

Financial Support

Supported by Grants from Canola Council of Canada, Flax Council of Canada, Agriculture and Agri-Food Canada, Dow AgroSciences and Western Grains Research Foundation and Canada Research Chairs Program collectively provided funding for this trial through the Growing Forward program of Agriculture and Agri-Food Canada. Also supported by NIH Grant HL 49373 and National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000127. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Conflict of interest

Peter Jones reported receiving grants from Advanced Foods and Materials Network (AFMNet), Danone, Enzymotec, Unilever, the Canadian Institutes of Health Research (CIHR), and Canada Research Chair Endowment (CRCE) of the Federal Government of Canada. Dr. Jones also serves as President of Nutritional Fundamentals for Health Inc., which markets plant sterols among other nutraceuticals.

The other authors did not report any conflicts of financial interest.

Authorship

PJJ is responsible for the integrity and the accuracy of the data and had full access to the complete data set in the study. Study concept and design: PJJ, VRR, and SP. Acquisition of data: PJJ, VRR, and SP, Analysis and interpretation of data: CRP, AS, PJJ, VRR, and SP. Drafting of the manuscript CRP, AS, PJJ, VRR and SP. Critical revision of the manuscript for important intellectual content and final approval of the manuscript: CRP, RQP, ASC, PJJ, VRR, and SP. Obtained funding: PJJ. Study supervision: PJJ, VRR, and SP. All authors reviewed the manuscript. All authors read and approved the final manuscript.

References

  1. 1.
    Ellegård LH, Andersson SW, Normén AL et al (2007) Dietary plant sterols and cholesterol metabolism. Nutr Rev 65:39–45PubMedCrossRefGoogle Scholar
  2. 2.
    Cífková R, Vaverková H, Filipovský J et al (2014) Summary of the European Guidelines on cardiovascular disease prevention in clinical practice prepared by the Czech Society of Cardiology. Cor Vasa 56:169–189CrossRefGoogle Scholar
  3. 3.
    Davidson MH (2013) Emerging low-density lipoprotein therapies: targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol 7:S11–S15PubMedCrossRefGoogle Scholar
  4. 4.
    Dadu RT, Ballantyne CM (2014) Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 10:563–575CrossRefGoogle Scholar
  5. 5.
    Abifadel M, Varret M, Rabès JP et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154–156PubMedCrossRefGoogle Scholar
  6. 6.
    Lose JM, Dorsch MP, Bleske BE (2013) Evaluation of proprotein convertase Subtilisin/Kexin Type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. Pharmacotherapy 33:447–460PubMedCrossRefGoogle Scholar
  7. 7.
    Benn M, Nordestgaard BG, Grande P et al (2010) PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease. 3 Independent studies and meta-analyses. J A Coll Cardiol 55:2833–2842CrossRefGoogle Scholar
  8. 8.
    Browning JD, Horton JD (2010) Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 51:3359–3363PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25(5):387–393PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Costet P, Cariou B, Lambert G et al (2006) Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 281(10):6211–6218PubMedCrossRefGoogle Scholar
  11. 11.
    Cariou B, Langhi C, Le Bras M et al (2013) Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab 10:4CrossRefGoogle Scholar
  12. 12.
    Brouwers MCGJ, Konrad RJ, van Himbergen TM et al (2013) Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis 23(11):1115–1121PubMedCrossRefGoogle Scholar
  13. 13.
    Richard C, Couture P, Desroches S et al (2011) Effect of the Mediterranean diet with and without weight loss on cardiovascular risk factors in men with the metabolic syndrome. Nutr Metab Cardiovasc Dis 21(9):628–635PubMedCrossRefGoogle Scholar
  14. 14.
    Bjermo H, Iggman D, Kullberg J et al (2012) Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 95:1003–1012PubMedCrossRefGoogle Scholar
  15. 15.
    Hooper L, Summerbell CD, Higgins JPT et al (2001) Dietary fat intake and prevention of cardiovascular disease: systematic review. Br Med J 322:757–763CrossRefGoogle Scholar
  16. 16.
    Swain JF, McCarron PB, Hamilton EF et al (2008) Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet. J Am Diet Assoc 108:257–265PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Senanayake VK, Pu S, Jenkins DA et al (2014) Plasma fatty acid changes following consumption of dietary oils containing n-3, n-6, and n-9 fatty acids at different proportions: preliminary findings of the Canola Oil Multicenter Intervention Trial (COMIT). Trials 15:136–147PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Lin L, Allemekinders H, Dansby A et al (2013) Evidence of health benefits of canola oil. Nutr Rev 71(6):370–385PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    FDA (food and drug administration) (2006) Unsaturated fatty acids from canola oil and reduced risk of coronary heart disease docket No. 2006Q-0091. http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm072958.htm. Accessed 21 Oct 2015
  20. 20.
    USDA (United States Department of Agriculture) (2012). Canola. http://www.ers.usda.gov/topics/crops/soybeans-oil-crops/canola.aspx#Consumption. Accessed 21 Oct 2015
  21. 21.
    Jones PJ, Senanayake VK, Pu S et al (2014) DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. Am J Clin Nutr 100:88–97PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Mifflin MD, St Jeor ST, Hill LA et al (1990) A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 51:241–247PubMedGoogle Scholar
  23. 23.
    Mackay DS, Jones PJH, Myrie SB et al (2014) Methodological considerations for the harmonization of non-cholesterol sterol bio-analysis. J Chromatogr B 957:116–122CrossRefGoogle Scholar
  24. 24.
    Cariou B, Le May C, Costet P (2011) Clinical aspects of PCSK9. Atherosclerosis 216:258–265PubMedCrossRefGoogle Scholar
  25. 25.
    Persson L, Cao G, Ståhle L et al (2010) Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 30:2666–2672PubMedCrossRefGoogle Scholar
  26. 26.
    Mayne J, Raymond A, Chaplin A et al (2007) Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 361:451–456PubMedCrossRefGoogle Scholar
  27. 27.
    Milne JC, Jirousek MR, Vu CB (2013) Methods of lowering proprotein convertase subtilisin/kexin type 9 (PCSK9). WO2013177536 A2. http://www.google.com/patents/WO2013177536A3?cl=en. Accessed Dec 2014
  28. 28.
    Graversen CB, Lundbye-Christensen S, Thomsen B et al. (2015) Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: a randomised study. Vascul Pharmacol. Article in press. doi: 10.1016/j.vph.2015.07.001
  29. 29.
    Li H, Ruan XZ, Powis SH et al (2005) EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int 67(3):867–874PubMedCrossRefGoogle Scholar
  30. 30.
    Grygiel-Gorniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. Nutr J 13(1):17PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Schulz R, Schlüter KD, Laufs U (2015) Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol 110(2):19CrossRefGoogle Scholar
  32. 32.
    Jump DB (2008) N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19(3):242–247PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Sun H, Samarghandi A, Zhang N et al (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 32:1585–1595PubMedCrossRefGoogle Scholar
  34. 34.
    Lakoski SG, Lagace TA, Cohen JC et al (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 94:2537–2543PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© AOCS 2015

Authors and Affiliations

  • Celia Rodríguez-Pérez
    • 1
    • 2
  • Vanu Ramkumar Ramprasath
    • 3
    • 4
  • Shuaihua Pu
    • 3
    • 4
  • Ali Sabra
    • 4
  • Rosa Quirantes-Piné
    • 2
  • Antonio Segura-Carretero
    • 1
    • 2
  • Peter JH Jones
    • 3
    • 4
    • 5
  1. 1.Department of Analytical Chemistry, Faculty of SciencesUniversity of GranadaGranadaSpain
  2. 2.Research and Development Functional Food Centre (CIDAF)Health Science Technological ParkGranadaSpain
  3. 3.Department of Human Nutritional SciencesUniversity of ManitobaWinnipegCanada
  4. 4.Richardson Centre for Functional Foods and NutraceuticalsWinnipegCanada
  5. 5.Department of Food SciencesUniversity of ManitobaWinnipegCanada

Personalised recommendations